Christopher Coss, PhD
College of Pharmacy
Res Asst Professor
Molecular Carcinogenesis and Chemoprevention
Christopher Coss, PhD, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where he brings a therapeutics perspective.His research focuses on cachexia therapeutics, endocrine-disease mechanisms and development of novel therapies for endocrine cancers. He also is exploring chemoprevention of prostate and hepatocellular carcinomas using novel hormonal approaches. Among his recent research efforts is the first report of the pharmacokinetics of AR-42, a new orally bioavailable, potent, hydroxamate-tethered phenylbutyrate class I/IIB histone deacetylase inhibitor that is now in early-phase clinical trials. Dr. Coss has co-authored several articles in well-respected publications, such as Investigational New Drugs, The American Association of Pharmaceutical Scientists Journal and Biochemistry.